Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Pulmonx Corporation (NASDAQ:LUNG) have been given an average recommendation of “Hold” by the ten brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $6.8071.

Several analysts have commented on LUNG shares. Lake Street Capital dropped their target price on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th.

Institutional Investors Weigh In On Pulmonx

Large investors have recently bought and sold shares of the company. Parkman Healthcare Partners LLC raised its stake in Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock worth $4,118,000 after buying an additional 404,022 shares during the period. Trexquant Investment LP grew its stake in Pulmonx by 140.0% in the first quarter. Trexquant Investment LP now owns 224,909 shares of the company’s stock valued at $1,514,000 after acquiring an additional 131,209 shares during the period. Nuveen LLC bought a new stake in shares of Pulmonx in the first quarter worth about $1,336,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Pulmonx by 32.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock worth $567,000 after acquiring an additional 53,148 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in shares of Pulmonx during the second quarter worth about $197,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Down 2.6%

Shares of NASDAQ:LUNG opened at $2.22 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The stock has a market cap of $91.58 million, a price-to-earnings ratio of -1.57 and a beta of 0.22. The company has a 50 day moving average of $1.92 and a 200-day moving average of $2.06. Pulmonx has a one year low of $1.31 and a one year high of $9.37.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. The business had revenue of $21.50 million for the quarter, compared to analyst estimates of $20.78 million. On average, sell-side analysts forecast that Pulmonx will post -1.55 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.